Catalogue identityDataset 2026.08.15.1

Azzalure

Galderma

This is the Azzalure identity captured in the dated Aesthetic Pass operational catalogue snapshot. Product-specific source verification is available at family level only.

Evidence status: Catalogue identity · family sources available

The clinical research edition

Go deeper into the formulation and evidence

Explore composition, mechanism, safety and study interpretations for the exact presentation below. These new clinical drafts have a separate review process; this identity profile’s approval does not extend to them.

Azzalure monograph ↗

Identity record

What is recorded

v2026.08.15.1
Record type
Operational catalogue identity
Recorded maker
Galderma
Classification
Neuromodulator
Material identity
abobotulinumtoxinA
Snapshot date
14 August 2026

Manufacturer and category are catalogue fields. They are not, by themselves, a regulatory classification or verification of the exact marketed presentation.

Family evidence available

This identity maps to Dysport / Azzalure

The family profile provides aliases and official family-level sources. Those sources do not automatically verify this exact variant, formulation, label, or market status.

Open family profile

Provenance

Family-level sources

3 sources · checked 14 August 2026

These sources support the linked family profile, not every property of this exact catalogue identity.

  1. Manufacturer

    1. Azzalure

    Galderma · European Union / international

    Open source ↗

    Supports: Azzalure identity and its naming relationship with Dysport in aesthetic markets.

  2. Approved label

    2. Azzalure 125 Speywood units — Summary of Product Characteristics

    electronic Medicines Compendium · United Kingdom

    Open source ↗

    Supports: Current UK prescribing-information context for the named product presentation.

  3. Approved label

    3. DYSPORT — United States drug label

    U.S. National Library of Medicine (DailyMed) · United States

    Open source ↗

    Supports: The United States DYSPORT identity, Galderma labeler context, and abobotulinumtoxinA naming.

Use boundary

What this record does not establish

  • Regulatory statusOnly within a source's named jurisdiction; family evidence does not establish status elsewhere.
  • Authenticity or supply chainA catalogue name cannot authenticate an individual box, lot, or seller.
  • Clinical suitabilityNo product selection, patient assessment, dose, protocol, or injection technique is provided.
  • Availability or equivalenceNames, formulations, units, and presentations can vary by market and over time.

Separate reference from record-keeping

Document the exact product and lot actually used

Aesthetic Pass records treatment identity, lot information, photos, and injection maps. The atlas itself never chooses a product or treatment.

Explore traceability